Back to top
more

Bionomics (BNOX)

(Delayed Data from NSDQ)

$0.27 USD

0.27
694,360

-0.01 (-4.48%)

Updated Oct 7, 2024 03:59 PM ET

After-Market: $0.26 -0.01 (-4.80%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BNOX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Bionomics Limited Unsponsored ADR [BNOX]

Reports for Purchase

Showing records 1 - 17 ( 17 total )

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

07/31/2024

Company Report

Pages: 10

BNC210''s Path to NDA Submission Defined With Phase 3 PTSD Study Launching in 4Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

07/18/2024

Daily Note

Pages: 8

Phase 3 AFFIRM-1 Study in SAD Kicks Into Gear as Patient Screening Begins; Topline Data in 3Q25

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

06/12/2024

Company Report

Pages: 10

Important Overhang Addressed; Phase 3 SAD Study to Start Shortly; PTSD Up Next

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 4

03/21/2024

Company Report

Pages: 9

Compelling Full ATTUNE PTSD Results Forge Pivotal Path Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 5

01/22/2024

Daily Note

Pages: 5

Pipeline Update Provides Detailed Roadmap For BNC210''s Path; We See BD as Big Component

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 6

12/07/2023

Company Report

Pages: 6

Psychometric Analysis Confirms SUDS Reliability in Anxiety Assessment; Phase 3 SAD Program Launches 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 7

10/16/2023

Company Report

Pages: 12

An Important Handshake We''ve Been Anticipating; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 8

10/03/2023

Company Report

Pages: 12

BNC210 Should Be First in Pivotal SAD Study as Comp Shares Plans; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 9

09/28/2023

Company Report

Pages: 10

Phoenix Rises With Core Data Foundations; PTSD Phase 2b Win; Upgrade to Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 10

08/07/2023

Daily Note

Pages: 6

Nothing to be SAD About; PALISADE-2 Data Underscore BNC210''s Potential

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 11

03/09/2023

Company Report

Pages: 8

Final PREVAIL SAD Data Point in Right Direction; EOP2 Meeting Planned for 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 12

12/19/2022

Company Report

Pages: 5

We Are SAD To Move To Sidelines; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 13

10/13/2022

Company Report

Pages: 8

BNC210 Close to Burst Into Speech; PREVAIL Top-Line Data in SAD by YE22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 14

09/06/2022

Industry Report

Pages: 11

Time to Step Up for These Catalysts; Making Real Differences

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 15

07/25/2022

Daily Note

Pages: 5

BNC210 Remains Differentiated, In Our Belief; PREVAIL Data Readout Expected by Year End

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 16

03/02/2022

Company Report

Pages: 6

F1H22 Results; We Are Happy About the SAD Data Later This Year; PTSD Data Soon After; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Bionomics Limited Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 17

01/10/2022

Company Report

Pages: 21

Welcome to the U.S.; Continuing Our Coverage With BNC210 Excitement; ADS Target to $54

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 35.00

Research Provided by a Third Party
// eof